BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32218467)

  • 1. Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth.
    Leventoux N; Augustus M; Azar S; Riquier S; Villemin JP; Guelfi S; Falha L; Bauchet L; Gozé C; Ritchie W; Commes T; Duffau H; Rigau V; Hugnot JP
    Sci Rep; 2020 Mar; 10(1):5504. PubMed ID: 32218467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of glioma and IDH1/IDH2 mutations.
    Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
    Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation.
    Lindemann C; Hackmann O; Delic S; Schmidt N; Reifenberger G; Riemenschneider MJ
    Acta Neuropathol; 2011 Aug; 122(2):241-51. PubMed ID: 21590492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
    Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
    Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas.
    Park CK; Park I; Lee S; Sun CH; Koh Y; Park SH; Kim JE; Yun H; Lee SH
    Oncotarget; 2015 Dec; 6(41):43653-66. PubMed ID: 26524630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas.
    Li J; Wang X; Chen L; Zhang J; Zhang Y; Ren X; Sun J; Fan X; Fan J; Li T; Tong L; Yi L; Chen L; Liu J; Shang G; Ren X; Zhang H; Yu S; Ming H; Huang Q; Dong J; Zhang C; Yang X
    Cancer Gene Ther; 2022 Aug; 29(8-9):1117-1129. PubMed ID: 34992215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
    Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
    Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
    Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
    Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells.
    Cuevas P; Díaz-González D; Sánchez I; Lozano RM; Giménez-Gallego G; Dujovny M
    Neurol Res; 2006 Mar; 28(2):127-30. PubMed ID: 16551428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression.
    Birner P; Toumangelova-Uzeir K; Natchev S; Guentchev M
    Folia Neuropathol; 2011; 49(2):88-93. PubMed ID: 21845536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
    Viswanath P; Najac C; Izquierdo-Garcia JL; Pankov A; Hong C; Eriksson P; Costello JF; Pieper RO; Ronen SM
    Oncotarget; 2016 Jun; 7(23):34942-55. PubMed ID: 27144334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
    Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
    Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.